RPRX analyst estimates
Royalty Pharma (RPRX) analyst ratings, the average price target and its range, and every firm's latest call.
RPRX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 7, 2026 | Morgan Stanley | Royalty Pharma price target raised to $67 from $65 at Morgan Stanley | $67.00 |
| Aug 6, 2026 | Morgan Stanley | Royalty Pharma price target raised to $65 from $64 at Morgan Stanley | $65.00 |
| Aug 6, 2026 | Goldman Sachs | Royalty Pharma price target raised to $66 from $59 at Goldman Sachs | $66.00 |
| Apr 21, 2026 | UBS | Royalty Pharma price target raised to $57 from $51 at UBS | $57.00 |
| Apr 10, 2026 | Morgan Stanley | Royalty Pharma price target raised to $63 from $61 at Morgan Stanley | $63.00 |
| Feb 27, 2026 | Seaport Global | Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen | $50.00 |
| Feb 12, 2026 | Morgan Stanley | Royalty Pharma price target raised to $61 from $56 at Morgan Stanley | $61.00 |
| Jan 30, 2026 | UBS | Royalty Pharma upgraded to Buy from Neutral at UBS | $49.00 |
| Dec 11, 2025 | Leerink Partners | Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' | $45.00 |
| Sep 30, 2025 | Goldman Sachs | Royalty Pharma initiated with a Buy at Goldman Sachs | $42.00 |
| Jul 10, 2025 | Morgan Stanley | Royalty Pharma price target raised to $54 from $51 at Morgan Stanley | $54.00 |
| Sep 4, 2024 | Goldman Sachs | Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX) | $51.00 |
| Jul 11, 2024 | Morgan Stanley | Royalty Pharma price target raised to $51 from $48 at Morgan Stanley | $51.00 |
| Jun 7, 2024 | Goldman Sachs | Royalty Pharma (RPRX) PT Raised to $50 at Goldman Sachs | $50.00 |
| Jun 3, 2024 | UBS | Royalty Pharma downgraded to Neutral from Buy at UBS | $28.00 |
- 5 firms rate RPRX: 5 buy, 0 hold, 0 sell.
- The average price target is $66.50 from 2 analysts, from $66.00 to $67.00.
Updated 2026-11-02 23:59 UTC